Skip to Content

Developmental Research and Career Development Awardees


Note: Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Basen-Engquist K, de Moor C. Evaluating fatigue of ovarian cancer patients using ecological momentary assessment. In Stone A, Shiffman S, Atienza A, Nebeling L (Eds.) The Science of Real-Time Data Capture: Self-Report in Health Research. Oxford University Press, New York, NY. [no PMID]
    [no link available]
  2. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM. Depression, anxiety and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78:302-8. PMID: 10985884.
  3. *Zhou BP, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. Her-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NFkappaB pathway. J. Biol Chem 2000; 275(11):8027-31. PMID: 10713122.
  4. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the functional assessment of cancer therapy – ovarian. J Clin Oncol 2001; 19(6):1809-17. PMID: 11251013.
    Full Text
  5. Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF 1/CIP-1), and p53. Gynecol Oncol 2001; 83(3):543-8. PMID: 11733969.
  6. Chen CM, Behringer RR. Cloning, structure and expression of the mouse Ovcal gene. Biochem Biophys Res Commun 2001; 286(5):1019-26. PMID: 11527402.
  7. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC Jr. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80(2):145-55, 2/2001. PMID: 11161852.
  8. Che M, Tornos C, Deavers MT, Malpica A, Gershenson DM, Silva EG. Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells. Int J Gynecol Pathol 20(4):323-8, 10/2001. PMID: 11603214.
  9. Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61(19):7264-7, 10/2001. PMID: 11585764.
  10. Miller BE, Barron BA, Dockter ME, Delmore JE, Silva EG, Gershenson DM. Parameters of differentiation and proliferation in adult granulosa cell tumors of the ovary. Cancer Detect Prev 25(1):48-54, 2001. PMID: 11270421.
  11. Gershenson DM. Advances in the management of early-stage epithelial ovarian cancer. American Society of Clinical Oncology 2001 Educational Book, 462-467, 2001. [no PMID]
  12. *Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185 (HER2) and induces Rac 1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 2001; 276(52):48679-92. Epub 2001 Oct 17. PMID: 11606575.
  13. Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH, Kim JW, Hu L, Xu J, Liu J, Lee JH, Lee SH. Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptisis. Oncogene 2001; 20(46):6700-6. PMID: 11709704.
  14. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol 2002; 21(3):461-8. PMID: 12168087.
  15. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, Wolf JK. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 85(2)(2):285-91, 5/2002. PMID: 11972389.
  16. Wolf JK, Coleman RL. Commentary on, Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYZ-015(dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. Vasey, et al. J Clin Oncol 2002;20:1562-9." Women's Oncol Rev 2:325-7, 2002. [no PMID]
  17. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3-10, 1/2002. PMID: 11777502.
  18. Silva EG, Tornos C, Malpica A, Deavers MT, Tortolero-Luna G, Gershenson DM. The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders. Int J Surg Pathol 10:33-9, 1/2002. PMID: 11927967.
  19. Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: A study of 99 advanced stage cases. Am J Surg Pathol 26:1129-41, 9/2002. PMID: 12218569.
  20. Gershenson DM. Irinotecan in epithelial ovarian cancer. Oncology 16:29-31, 2002. PMID: 12109803.
  21. Donato M, Gershenson DM. Ovarian cancer: A review. Oncology Case Reports & Review 14, 2002. [no PMID]
  22. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8:2924-32. PMID: 12231537.
  23. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JL, Buller RE, Hendrix MJ, Sood AK, Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002; 8:3193-7. PMID: 12374688.
  24. Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian cancer. Cancer Biol Ther 2002; 1(5):511-7. PMID: 12496479.
  25. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. 2002; Cancer 95:808-15. PMID: 12209725.
  26. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 2002; 86:85-90, 2002. PMID: 12079305.
  27. Cooper BC, Sood AK, Davis C, Ritchie J, Sorosky JI, Anderson B, Buller RE. Preoperative CA125 levels: An independent prognostic factor in patients with Stage I epithelial ovarian cancer. Obstet Gynecol 100:259-64, 2002. PMID: 1518770.
  28. *Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJC. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: Implications for anti-vasculogenic therapy. Cancer Biol Ther 2002; 1(6):661-664. PMID: 12642690.
  29. *Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsel ME, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer – do they change over time? Gynecol Oncol 2002; 87(1): 118-28. PMID: 12468352.
  30. *Fang XJ, Yu S,Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002; 22: 2099-110. PMCID: PMC133668.
  31. Huang X, Lin T, Gu J, Shang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 2002; 9(20):1379-86. PMID: 12365003.
  32. Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol. 2002 Jun;29(3 Suppl 11):62-70. PMID: 12138399.
  33. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57(1):246-54. PMID: 12909240.
  34. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 8(21):19245-56. PMID: 12637505.
  35. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003; 13(6-10):399-404. PMID: 12725530.
  36. Ludes-Meyers JH, Bednarek AK, Popescu N, Bedford MT, Aldaz CM. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenetics and Genome Research 100:101-110, 2003. PMID: 14526170.
  37. Boling W, Fouladi RT, Basen-Engquist K. Health-related quality of life in gynecological oncology: instruments and psychometric properties. Int J Gynecol Cancer 13:5-14, 2003. PMID: 12631213.
  38. Pask AJ, Behringer RR, Renfree MB. Expression of DMRT1 in the mammalian ovary and testis--from marsupials to mice. Cytogenet Genome Res 101:229-236, 2003. PMID: 14684988.
  39. Silva EG, Deavers MT, Parlow AF, Gershenson DM, Malpica A. Calcifications in ovary and endometrium and their neoplasms. Mod Pathol 16(3):219-22, 3/2003. PMID: 12640101.
  40. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: Initial clinical results. J Nucl Med 44:700-7, 5/2003. PMID: 12732670.
  41. Kaye S, Gershenson D, Hung M, Seiden M. Discussion: Molecular therapeutics and pharmacogenomics. Proceedings of the Eighth Biennial International Forum on Ovarian Cancer. Gynecol Oncol 88:S93-S96, 2003. [no PMID]
  42. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Jr. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 2003; 983:268-77. PMID: 12724231.
  43. *Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 2003; 78:11962-9. PMID: 12554733.
  44. *Zhou C, Smith JL, Liu J. Role of BRCA 1in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22(16):2396-404. PMID: 12717416.
  45. *Zhou C, Liu J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells. Biochem Biophys Res Commun 2003; 303(1):130-6. PMID: 12646176.
  46. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decrease transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 2003; 22(36): 5694-701. PMID: 12944918.
  47. Deavers MT, Malpica A, Liu J, Broaddus R. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 2003; 16(6):584-90. PMID: 12808064.
  48. Wang L, Deavers MT, Malpica A, Silva EG, Liu J. Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol 2003; 11(2);174-6. PMID: 12778004.
  49. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 2003; 22(6) 1241-5. PMID: 12738989.
  50. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum resistance and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 2003; 21:2856-9. PMID: 12885801.
  51. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanian MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S , Old LJ. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83. PMID: 14522938.
  52. Lutgendorf SK, Cole S, Costanza E, Bradley S, Coffin J, Jabbari S, Rainater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate cascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003; 9:4514-21. PMID: 14555525.
  53. Geisler JP, Goodheart MJ, Sood AK, Holmes, RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 2003; 98:2199-206. PMID: 14601090.
  54. Cao SN, Chang KH, Luthra R, Liu J. Frameshift mutations in the bax gene are not involved in the development of ovarian endometroid carcinoma. Mod Pathol 2003; 16(10): 1048-52. PMID: 14559989.
  55. Kabbani W, Deavers MT, Malpica A, Burke TW, Liu J, Ordonez NG, and Silva EG. Uterine tumor resembling ovarian sex cord tumor presenting as a cervical mass: A case report with tubular pattern mimicking cervical adenocarcinoma. Int J Gyn Pathol 22(3):297-302, 2003. PMID: 12819400.
  56. Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22(4):671-7, 2/2004. PMID: 14966090.
  57. Ramondetta LM, Tortolero-Luna G, Bodurka DC, Sills D, Basen-Engquist K, Gano J, Levenback C. Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer 14(4):580-8, 7/2004. PMID: 15304150.
  58. Basen-Engquist K. Sexuality after gynecologic cancer. OncoLog 49(10):8, 2004. [no PMID]
  59. Ludes-Meyers JH, Bednarek AK, Shadler KL, Drane J, Bedford MT, Aldaz CM. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 23:5049-5055, 2004. PMID: 14526170.
  60. Samanta AK, Huang HJ, Bast RC Jr, Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem 2004; 279(9): 7576-83. PMID: 14662759.
  61. Chen CM, Behringer RR. Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev 18:320-332, 2004. PMCID: PMC338284.
  62. Chen CM, Chang JJ, Behringer RR. Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts. Oncogene 2004; 23(46):7722-5. PMID: 15334065.
  63. Markman M, Gershenson DM, Wolf J. Controversies in Ovarian Cancer. ACOG Update 30:1-9, 2004. [no PMID]
  64. Slomovitz B, Soliman P, Wolf J. New standards for treating recurrent ovarian cancer. NOCC 19 (Summer):5, 2004. [no PMID]
  65. Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin RE. Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: A case report. Gynecol Oncol 92:365-7, 1/2004. PMID: 14751187.
  66. Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R. Brain metastases in patients with ovarian carcinoma: Prognostic factors and outcome. J Neurooncol 66:313-25, 2/2004. PMID: 15015663.
  67. Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res 10(8):2681-6, 4/2004. PMID: 15102671.
  68. Euscher ED, Silva EG, Deavers MT, Elishaev E, Gershenson DM, Malpica A. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol 28:1217-23, 9/2004. PMID: 15316322.
  69. Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22(17):3517-23, 9/2004. PMID: 15337800.
  70. Tangjitgamol S, See HT, Manusirivithaya S, Levenback CF, Gershenson DM, Kavanagh JJ. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 14(5):804-14, 9/2004. PMID: 15361188.
  71. Gershenson DM. Special feature: Unilocular ovarian cysts in postmenopausal women: surgery versus expectant management. OB/GYN Alert 20(9):71-72, 2004. [no PMID]
  72. *Carmack Taylor CI, Basen-Engquist K, Shinn KH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004; 22(5):881-9. PMID: 14990644.
  73. Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K, Nozawa S. A novel retinoid, 4-[3,5-bis (trimethylsilyl)benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Gynecol Oncol 2004; 94(3):643-9. PMID: 15350353.
  74. *Liu S, Yu S, Hasegawa Y, LaPushin R, Xu HJ, Woodgett JR, Mills GB, Fang X. Glycogen synthase kinase 3b is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem. 2004 Dec 3;279(49):51075-81. Epub 2004 Oct 1. PMID: 15466414.
  75. Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W, Pasqualini R. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies of ovarian cancer patients. Oncogene, 2004 Nov 25;23(55):8859-67. PMID: 15480432.
  76. Freedman RS, Deavers MT, Liu J, Wang E. Peritoneal inflammation -- A microenvironment for epithelial ovarian cancer (EOC). J Translational Med 2(1):23, 2004. PMCID: PMC459521.
  77. Rosen DG, Wang L, Jain AJ, Lu KH, Luo R, Liu J, Bast RC Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression free survival. Clin Cancer Res 2004; 10:6559-66. PMID: 15475444.
  78. *Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng Z. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004; 64(13):4577-84. PMID: 15231669.
  79. Cai KO, Albarracin CT, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 2004; 35(5):552-9. PMID: 15138928.
  80. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17(7):790-7. PMID: 15073602.
  81. Baykal A, Thompson JA, Xu XC, Hahn WC, Deavers MT, Malpica A, Gershenson DM, Silva EG, Liu J, In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004; 11(2):297-302. PMID: 14719058.
  82. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometriod cancer. Mod Pathol 2004; 17(1):75-80. PMID: 14631366.
  83. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated siRNA silencing against Her-2/neu gene expression. J Biol Chem 2004; 279:4339-45. PMID: 14625284.
  84. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LN, Burke TW, Gershenson DM, Lu KH. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 2004; 95:32-6. PMID: 15385107.
    Full Text
  85. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and the relationship with microsatellite instability phenotype. Oncol Reports. 2004 Dec;12(6):1217-9. PMID: 15547740.
  86. Sood AK, Coffin JE, Schneider GB, Fletcher MS, Deyoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJC. Biological significance of focal adhesion kinase in ovarian cancer. Am J Pathol 2004; 165(4):1087-95. PMCID: PMC1618649.
  87. Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 2004; 10:6080-5. PMID: 15447993.
  88. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case control analysis of toxicity. Am J Clin Oncol 2004; 27:14-8. PMID: 14758127.
  89. *Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ. Functional role of matrix metalloproteinase in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004; 190:899-909. PMID: 15118611.
    Full Text
  90. Frausto SD, Geisler JP, Fletcher MS, Sood AK. Late recurrence of juvenile granulose cell tumor of the ovary. Am J Obstet Gynecol 2004; 191:366-7. PMID: 15295395.
  91. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004; 10:5145-50. PMID: 15297418.
  92. Ghadersohi A, Odunsi K, Lele S, Collins Y, Greco WR, Winston J, Liang P, Sood AK. Prostate derived Ets transcription factor shows better tumor-association that other cancer-associated molecules. Oncol Rep 2004; 11(2):453-8. PMID: 14719083.
  93. Landen CN, Klingelhutz A, Coffin JE, Sorosky JL, Sood AK. Genomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer Biol Ther. 2004 Dec;3(12):1250-3. Epub 2004 Dec 14. PMID: 15477760.
  94. Qian F, Grijatic S, Jagar E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K. Th1/Th2 CD4+ Tcell responses against NY-ESO-1 in HLA-DPB1 *0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 2004 Nov 3;4:12. PMID: 15521719.
  95. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004; 64:3550-8. PMID: 15150111.
  96. *Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D, Liu J, Naora H. Lessons from border cell migration in the Drosophila ovary: a role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci USA 2004; 101:8144-9. PMCID: PMC419571.
  97. Chen CM, Behringer RR. OVCA1: tumor suppressor gene. Curr Opin Genet Dev, 2005 Feb;15(1):49-54. PMID: 15661533.
    Full Text
  98. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer. 2005 Jun 27;5(1):64. PMCID: PMC1173095.
  99. Gourley C, Paige AJ, Taylor KJ, Scott D, Francis NJ, Rush R, Aldaz CM, Smyth JF, Gabra H. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 26(6):1681-9, 6/2005. PMID: 15870886.
  100. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 390(Pt 1):125-36, 8/2005. PMCID: PMC1184568.
  101. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH and Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005; 2;4:7. PMCID: PMC549074.
  102. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ. Response of recurrent uterine high-grade malignant mixed mullerian tumor to letrozole. Int J Gynecol Cancer. 2005 Nov;15(6):1243-1248. PMID: 16343224.
  103. Hoestra AV, Riben MW, Frumovitz M, Liu J, and Ramirez PT. Well-differentiated papillary mesothelioma of the peritoneum: A pathological analysis and review of the literature. Gynecol Oncol. 2005 Jul;98(1):161-7. Review. PMID: 15894368.
  104. Yoshida H, Liu J, Samuel S, Cheng W, Rosen D, Naora H. Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):77-85. Epub 2005 Nov 18. PMID: 16298470.
    Full Text
  105. Rosen DG and Liu J. Prognostic markers in epithelial ovarian cancer. Tumors 14-22, 4/2005. [no PMID]
  106. Kamat AA, Sood AK. The merits of vascular targeting for gynecologic malignancies. Curr Oncol Rep 7(6):444-50, 11/2005. PMID: 16221381.
  107. Naora H, Montell DJ. Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer 5:355-366, 2005. PMID: 15864277.
  108. Naora H. Developmental patterning in the wrong context: The paradox of epithelial ovarian cancers. Cell Cycle 4(8):1033-5, 2005. PMID: 16082202.
  109. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7657, 11/2005. PMID: 16278384.
  110. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of over-expression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19 Pt 1):6880-6888, 2005. PMID: 16203778.
  111. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC Jr, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 2005 Aug 1;65(15):6701-10. PMID: 16061651.
  112. Canada AL, Parker PA, de Moor JS, Basen-Engquist K, Ramondetta LM, Cohen L. Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer. Gynecol Oncol 101(1):102-7, 4/2006. PMID: 16256181.
  113. de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med 68:555-62, 7/2006. PMID: 16868264.
  114. Badr H, Basen-Engquist K, Carmack Taylor CL, de Moor C. Mood states associated with transitory physical symptoms among breast and ovarian cancer survivors. J Behav Med 29:a75, 10/2006. PMID: 16705484,
  115. Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response. Int J Gynecol Cancer 16 Suppl 1:111-7, Jan-Feb 2006. PMID: 16515577.
  116. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006 Mar 15;12(6):1707-14. PMID: 16551853.
  117. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006 Nov;103(2):512-7. Epub 2006 Jun 5. PMID: 16750560.
  118. Sood AK. Location matters. Gynecol Oncol. 2006 Jun;101(3):378-9. PMID: 16723288.
  119. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X. Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene {alpha} in Ovarian Cancer. Cancer Res. 2006 Mar 1;66(5):2740-8. PMID: 16510595.
  120. Chang KH, Albarracin C. Luthra R, Zheng W, Wang L, Malpica A, Deavers MT, Silva EG, and Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):178-82. PMID: 16445630.
  121. *Tanyi JL, Croetzer D, Wolf J, Yu S, Hasegawa Y, Lahad J, Cheng KW, Umezu-Goto M, Prestwich GD, Morris A, Newman RA, Felix EA, Lapis R, Mills GB. Functional lipidomics: lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. In: Functional Lipidomics, Feng L and Prestwich GD, eds., CRC Press/Taylor & Francis, New York, 101-123 (2006). [no PMID]
    [no link available]
  122. Sood A, Lu C, Jennings N, Armaiz-Pena G, Bornmann W, Ravoori M, Merritt W, Lin Y, Mangala S, Tae JK, Coleman R, Landen C, Li Y, Felix E, Newman R, Lloyd M, Gershenson D, Kundra V, Lopez-Berestein G, Cole S, Arevalo J, Takahashi R, Lutgendorf S. Stress and the spread of ovarian cancer in mice. Cancer Biol Ther 5(8):898, 2006. [no PMID]
  123. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 4/2006. PMCID: PMC1600675.
  124. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2006. PMID: 17161674.
  125. Fu S, Kavanagh JJ, Hu W, Bast RC Jr. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1717-32. PMID: 17009963.
  126. Fu S, Hu W, Kavanagh JJ, Bast RC Jr. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb;10(1):77-85. PMID: 16441230.
  127. Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006 Mar;100(3):495-500. Epub 2005 Oct 20. PMID: 16242759.
  128. Komar CM, Zacharachis-Jutz F, Cretekos CJ, Behringer RR, Rasweiler JJ IV. Polarized ovaries of the long-tongued bat, Glossophaga soricina-a novel model for studying ovarian development, oocyte pool maintenance, folliculogenesis, and ovulation. Anatomical Record 290:1439-1448, 11/2007. PMID: 17929278.
  129. Gershenson D, Wong K. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. 2007 ASCO Educational Book 23(5-6):pp. 313-317, 2007. [no PMID]
  130. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9(6):479-86, 6/2007. PMCID: PMC1899257.
  131. Song Y, Wilkins P, Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J, Barbour SE, Fang X. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 406(3):427-36, 9/15/2007. PMCID: PMC2049037.
  132. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 17(4):739-63, 2007. PMID: 17309673.
  133. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol. 2007 Aug;31(2):441-9. PMID: 17611702.
  134. Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol. 2007 May;170(5):1594-606. PMCID: PMC1854954.
  135. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. Epub 2008 Nov 11. PMCID: PMC2720766.
  136. Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 104(3):768-78, 3/2007. PMCID: PMC1851902.
  137. Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 9(13):1-12, 2007. PMID: 17477890.
  138. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 6/1/2007. PMID: 17538174.
  139. Song F, He M, Li H, Qian B, Wei Q, Zhang W, Chen K, Hao X. A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000. Cancer Causes Control. 2008 Jun;19(5):443-50. Epub 2007 Dec 20. PMID: 18095173.
  140. Zheng L, Wei Q, Zhou B, Yang L, Liu ZL. Synthesis of 1,1,2-triphenylethylenes and their antiproliferative effect on human cancer cell lines. Anticancer Drugs. 2007 Oct;18(9):1039-44. PMID: 17704654.
  141. Jackson EF, Esparza-Coss E, Wen X, Ng CS, Daniel SL, Price RE, Rivera B, Charnsangavej C, Gelovani JG, Li C. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):830-8. Epub 2007 Mar 26. PMCID: PMC1997292.
  142. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-376, 2007. PMID: 18057520.
  143. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis. Int J Gynecol Pathol. 2007 Oct;26(4):404-9. PMID: 17885490.
  144. Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007 Nov 1;67(21):10389-96. PMID: 17974982.
  145. Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF, Johanning GL. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. 2007 Jan 1;120(1):81-90. PMID: 17013901.
  146. Wang-Johanning F, Huang M, Liu J, Rycaj K, Plummer JB, Barnhart KF, Satterfield WC, Johanning GL. Sheep stromal-epithelial cell interactions and ovarian tumor progression. Int J Cancer. 2007 Nov 15;121(10):2346-54. PMID: 17657741.
  147. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008 Jul-Aug;18(4):600-14. Epub 2007 Sep 25. Review. PMID: 17894799.
  148. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):325-38. Review. PMID: 17362310.
  149. Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 2007 Jul 15;13(14):4098-104. PMID: 17634535.
  150. Laguë MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Doré M, Huneault LM, Richards JS, Boerboom D. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 29(11):2062-72, 11/2008. PMCID: PMC2577137.
  151. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477-479, 4/2008. PMCID: PMC2346589.
  152. Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, Dent P, Kordula T, Zhou H, Fang X. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J 22(8):2639-51. e-Pub 3/24/2008. PMCID: PMC2493458.
  153. Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res 25(10):2272-82, 10/2008. PMID: 18509599.
  154. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Bützow R, Croce CM, Coukos G, Zhang L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307-14, 12/15/2008. PMID: 19074899.
  155. Lu C, Shahzad MMK, Wang H, Landen CN Jr, Kim SW, Allen J, Nick AM, Jennings N, Kinch Ms, Bar-Eli M, Sood AK. EphA2 Overexpression Promotes Ovarian Cancer. Cancer Biol Ther 7(7):1098-103, 7/2008. PMCID: PMC2705979.
  156. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 1/2008. PMID: 19072449.
  157. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 9/2008. PMCID: PMC2517641.
  158. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):995-1005. Epub 2008 Jan 14. Review. PMID: 18195328.
  159. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008 Dec;76(10):1081-92. Epub 2008 Jul 2. PMCID: PMC2593124.
  160. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth. Clin Cancer Res. 2008 Sep 1;14(17):5437-5446. PMID: 18765535.
  161. Gershenson DM, Ramirez P. Gynecologic Tumors. The Merck Manual Online Medical Library: Home Edition for Patients and Caregivers,, 5/2009. [no PMID]
  162. Gershenson DM, Ramirez P. Gynecologic Tumors. The Merck Manual Online Medical Library: The Merck Manual for Healthcare Professionals,, 5/2009. [no PMID]
  163. Merritt WM, Urbauer DL, Sood AK. Dicer and Drosha in ovarian cancer. Response to Correspondence from Kobel M, Gilks CB, Huntsman DG. The New England Journal of Medicine:1150-1151, 2009. PMID: 19279349.
  164. Rampurwala M, Ravoori MK, Wei W, Johnson VE, Vikram R, Kundra V. Visualization and Quantification of Intraperitoneal Tumors by In vivo Computed Tomography Using Negative Contrast Enhancement Strategy in a Mouse Model of Ovarian Cancer. Translational Oncology 2(2):96-106, 5/2009. PMCID: PMC2670577.
  165. Kwong J, Chan FL, Wong KK. The inflammatory cytokine tumor necrosis factor-alpha confers precancerous phenotype in a organoid model of normal human ovarian surface eipithelial cells. Neoplasia 11(6):529-541, 6/2009. PMCID: PMC2685442.
  166. Ko SY, Guo H, Barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 15(13):4336-47, 7/2009. PMID: 19458052.
  167. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res. 2009 Jan 15;15(2):492-501. PMID: 19147754.
  168. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 Is Dispensable for Mouse Development and Reproduction. PLoS ONE. 2009;4(3):e4675. Epub 2009 Mar 5. PMCID: PMC2650410.
  169. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009 Sep;22(9):1243-50. Epub 2009 Jun 12. PMCID: PMC2736318.
  170. Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009 Jul 14. [Epub ahead of print]. PMID: 19608149.
  171. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9. Epub 2008 Dec 25. PMID: 19110234.
  172. Merritt WM, Danes CG, Shahzad MMK, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Lingegowda SM, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biology and Therapy. In Press. [no PMID]
  173. Gershenson DM. Rare Ovarian Tumors. US Obstetrics & Gynecology. In Press. [no PMID]
  174. Roma AA, Malpica A, Deavers MT, Gershenson DM, Silva EG. Ovarian serous borderline tumors with a predominant micropapillary/cribriform pattern are aggressive neoplasms with an increased risk for low grade serous carcinoma. Int J Gynecol Pathol. In Press. [no PMID]
  175. Huh Shinn E, Carmack Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Basen-Engquist K. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliative and Supportive Care. In Press. [no PMID]

© 2014 The University of Texas MD Anderson Cancer Center